Biomarkers in bladder cancer: Translational and clinical implications

Liu, Cheng; Davison, Darrell D.; Adams, Julia; López-Beltrán, Antonio; Wang, Lisha; Montironi, Rodolfo; Zhang, Shaobo

doi:10.1016/j.critrevonc.2013.08.008

Cited by 89 publications

(74 citation statements)

References 374 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Activation of the HER2 receptor, following autophosphorylation of the tyrosine kinase residues results in the activation of intracellular pathways [14][15][16][17][18][19][20] that promote proliferation, survival, mobility, and migration of tumor cells [21,22] (Fig. 1).…”

Section: Her2 and Bcmentioning

confidence: 99%

Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review

et al. 2018

View full text Add to dashboard Cite

Although human epidermal growth factor receptor 2 (HER2) plays a prognostic and predictive role in breast and gastric cancer, its function in bladder cancer (BC) is still controversial. A comprehensive review of the literature has been carried out. An electronic search of databases from PubMed, Scopus, Google Scholar was implemented. The search terms were: “BC,” “bladder carcinoma,” “bladder neoplasm,” “human epidermal growth factor 2,” “HER2,” “HER-2,” “c-erbB-2,” “c-erbB2,” “erbB-2,” “erbB2,” “neu,” “marker,” “biomarker,” and “prognosis”. Results of the review consented to (a) summarize the available data on HER2 a predictor of recurrence and/or progression free survival on univariate and multivariate analysis, (b) explore the related issues in assessing HER2 status on these tumor samples, since they may severely impair its predictive function, and (c) report the state-of-the art of HER2 as a putative therapeutic target in BC and especially non-muscle invasive BC. HER2 stands out for being a prognostic factor as well as a therapeutic target in various cancers. Data from the literature concerning its use in BC provide conflicting results, probably due to the inherent complexity of BC biology. Efforts should be made to establish a suitable tumor-specific scoring system, and to assess single drugs’ efficacy in well-designed clinical trials.

show abstract

Section: Her2 and Bcmentioning

confidence: 99%

Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Despite efforts in establishing tissue biomarkers that may assist urological surgeons in selecting patients in need for early radical surgery and (neo-)adjuvant chemotherapy, the major findings in this field have had little clinical and translational impact so far 7,8 . Moreover, it is tempting to speculate that loss of AQP3 in UBC may be associated with resistance to apoptotic stimuli, as previously shown for AQP 8 and 9 in hepatocellular carcinoma 13 .…”

Section: Discussionmentioning

confidence: 99%

“…In the past 2 decades, a plethora of urothelial carcinoma-associated biomarkers have been identified, including growth factors and their cognate receptors, oncogenes, oncoproteins, tumor suppressor genes, hormone receptors, proliferation and apoptosis markers, and cell adhesion molecules 7 . However, the diagnosis and therapeutic management of patients with bladder cancer continues to be based primarily on conventional clinical and pathological tumour staging and grading.…”

Section: Discussionmentioning

confidence: 99%

Loss of AQP3 protein expression is associated with worse progression-free and cancer-specific survival in patients with muscle-invasive bladder cancer

et al. 2015

View full text Add to dashboard Cite

Methods:Retrospective single-center analysis of the oncological outcome of patients following radical cystectomy (Cx) due to MIBC was performed.Immunohistochemistry was used to assess AQP3 protein expression in 100 Cx specimens. The clinical value of the marker was analyzed in relation to progression, cancer-specific and overall survival using Kaplan-Meier and multivariate Cox regression analysis (CRA). Results:Loss of or weak AQP3 expression was associated with a statistically significantly worse PFS (19% vs. 75%, p=0.043) and CSS (18% vs. 75%, p=0.030) and, alongside lymph node involvement, was an independent predictor of PFS (HR 2.872, CI: 1.058 -7.796, p=0.038) and CSS (HR 3.332, CI: 1.221 -9.089, p=0.019) in CRA. Conclusions may be limited by the size of the patient cohort and the restricted statistical power of the study. Conclusions:Although the results of the study would be strengthened by a larger, more appropriately powered, prospective, multi-institutional study, our findings strongly suggest that AQP3 expression status may represent an independent predictor of PFS and CSS in MIBC and may help select patients in need for (neo-)adjuvant chemotherapy.

show abstract

“…The ratio of men to women that develop bladder cancer is approximately 3:1 (Jemal et al, 2011). When first diagnosed, more than 80% of bladder tumours are non-muscle invasive papillary tumours (Ta, T1) and 70% of them are non-invasive to lamina propria (Ta) that have an excellent prognosis (Millán-Rodríguez et al, 2000;Ahmadi et al, 2012;Cheng et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Are Bladder Neoplasms More Aggresive in Patients with a Smoking-related Second Malignancy?

Ötünçtemur¹,

Köklü²,

Özbek³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Relationships between smoking and bladder neoplasms, one of the common malignancies, are well-known. Different smoking-related malignancies may occur together. In this study, we evaluated the stage and grade of bladder neoplasms in patients also featuring lung or larynx cancer. Materials and Methods: From January 2006 to February 2012, patients who underwent surgery for bladder neoplasms in our clinic were screened retrospectively. In the evaluation, 5 patients had larynx cancer and 20 patients have lung cancer in addition, all having been smoking for a long time. The bladder tumor stage and grade were investigated in these 25 cases. Results: Mean age of patients was 66.8 (49-78). In the evaulation, all of 5 patients who had larnyx cancer also had high grade urothelial cancer. One had T2 urothelial, and 3 T1 urothelial cancer. In the same way, all of the 20 patients with lung cancer also have high grade urothelial cancer, three T2, and 13 T1. Bladder cancer stage and grade were determined to be significantly increased in patients with concomitant bladder and lung or larynx cancer. Conclusions: In the patients who have smoking releated second malignancy, bladder cancer prognosis appears more aggressive. We now need a larger series and multi-center studies for understanding relevant pathophysiology.

show abstract

Biomarkers in bladder cancer: Translational and clinical implications

Cited by 89 publications

References 374 publications

Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review

Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review

Loss of AQP3 protein expression is associated with worse progression-free and cancer-specific survival in patients with muscle-invasive bladder cancer

Are Bladder Neoplasms More Aggresive in Patients with a Smoking-related Second Malignancy?

Contact Info

Product

Resources

About